We’re kicking off the first in a mini-series of expert interviews from the 2016 San Antonio Breast Cancer Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound that shows preclinical promise in several cancers including multi-drug resistant metastatic breast cancer.
It has a novel mechanism of action:
“Interestingly, it was the only molecule, out of the 150,000 we screened that seemed to work through this pathway.”
To go from “bench to bedside,” and take this drug into the clinic now requires funding beyond what academia can provide.
If you’re at #JPM17 and into early stage VC funding or are in pharma/biotech business development BD&L and are on the look out for an innovative new licensing/investment deal, this post is for you.
What makes this a great story is I heard that one “missing piece of the jigsaw” in working out the pathway through which the drug worked came from unrelated research presented at a seminar on wound healing in zebrafish!
As a 2013 article by Robin McKie in The Observer notes, zebrafish (Danio rerio) share 70% of our genes, which makes them pretty cool research models. They are also transparent.
Hearing this anecdote reminded me of my conversation with Dr William Pao that you can hear on Episode 3 of the Novel Targets Podcast where he astutely said:
“You never know where things are going to lead, you just have to be able to take advantage of them.”
That could also be a metaphor for life.
Science is about making sense of connections and patterns, which is why funding of basic science is so important. A piece of work by one researcher can unlock a breakthrough by another in a totally unrelated area.
While I was doing this SABCS16 interview, I was also reminded of the story behind the development of enzalutamide, and how AACR past-president Dr Charles Sawyers pitched his UCLA drug discovery work to several major pharma companies, without success, until Dr David Hung at Medivation took the risk… and the rest is history.
What makes that story so surprising is at the time Dr Sawyers already had a track record of success with his work on the development of imatinib!
It was a privilege to talk with a senior scientist at #SABCS16 who has thought outside of the box, made scientific connections, and in the process developed a new drug that shows exciting preclinical promise.
Improving the outcome for cancer patients requires the translation of basic science into new products that enter clinical trials.
I do hope funding will be forthcoming to move this first-in-class drug into the clinic so that’s its potential can be fully evaluated.